William Beaumont Hospital
Royal Oak, Michigan, 48073, United States
NCT Number: NCT00321295
Congestive heart failure (CHF) is a medical condition that is due to left ventricular systolic dysfunction (LVSD). LVSD is a decreased ability of the heart to pump blood forward. There are 5 million people in the United States that have CHF and 52,828 new cases are diagnosed annually. There are 995,000 hospital visits and 52,828 deaths annually due to CHF. Previous studies have shown that people with this condition are at a higher risk for complications immediately after any type of heart surgery than are normal individuals. This includes increased dependence on medications and devices to improve the pumping function of the heart and blood pressure. Additionally, they also have longer lengths of hospital stay and higher rates of death compared to normal individuals.
Some patients with LVSD not only have a decreased pumping ability of the heart, they also have an inefficient pumping function. These patients have been shown to benefit from a device therapy known as biventricular pacing. Biventricular pacing involves simultaneously electrically stimulating the two major pumping chambers of the heart known as ventricles using a pacemaker and wires. This causes a more coordinated contraction of the heart chambers resulting in improvement in the pumping ability of the heart and blood pressure. Studies have confirmed that in these patients, implantation of a biventricular pacemaker improves patients' symptoms and quality of life as well as decreasing a need for future hospitalizations. Whether biventricular pacing in patients with LVSD improves patient outcomes after heart surgery has not been investigated.
Some patients temporarily develop slow heart rates after cardiovascular surgery. These slow heart rates can cause a decrease in the blood pumped from the heart and result in low blood pressures. Therefore, all patients undergoing cardiovascular surgery, regardless of left ventricular function, receive temporary pacing wires that are placed on one of the ventricles during the surgery. Temporary pacing will result in an increase in heart rate and improvement in the amount of blood pumped by the heart and in blood pressure. The placement of these wires is precautionary as only a few patients need to be paced for slow heart rates. Once patients are felt to no longer require them, the wires are easily removed. The purpose of this study is to determine whether biventricular pacing immediately after heart surgery in patients with LVSD will improve in-hospital outcomes.
Patients that are scheduled for heart surgery and meet the inclusion criteria will be approached for consent to participate in this study. Once consented, they will be randomized to one of three treatment arms: usual care, RV pacing (single ventricle pacing), or biventricular pacing. Randomization is a process similar to picking numbers out of a hat. The patients will then undergo surgery as scheduled. During the surgery, the patients will receive the temporary pacing wires on both ventricles instead of one. Immediately after surgery, the patients will receive either usual care, RV pacing, or biventricular pacing depending upon the treatment arm that they were randomized to. The pacing wires will be removed as soon as the patients become stable as per routine. The clinical, operative, and in-hospital characteristics of these patients will be recorded on specialized forms. The characteristics of those that received biventricular pacing will be compared to those that had RV or no pacing to see whether there was any benefit to this mode of therapy.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Royal Oak, Michigan, 48073, United States
Biventricular (BiV) pacing has been shown to have acute and chronic benefits in a subset of patients with CHF (3-6). Those that have been shown to benefit from this mode of therapy have left ventricular systolic dysfunction with a widened QRS duration on the electrocardiogram. Acute hemodynamic studies comparing patients at baseline with either right ventricular (RV) or BiV pacing show significant improvements in the systolic blood pressure and cardiac output in patients with BiV pacing compared to either RV pacing or baseline measurements (3, 4). Furthermore, BiV pacing was associated with decrease in the pulmonary capillary wedge pressure (PCWP) and diastolic mitral regurgitation. These acute hemodynamic benefits are sustained and manifest as improvements in clinical symptoms. The Multisite Stimulation in Cardiomyopathies (MUSTIC) study showed that BiV pacing was associated with a 23% increase in the distance walked in six minutes (P<0.001), a 32% increase in the quality-of-life score (P<0.001), an 8% increase in the peak oxygen uptake (P<0.03), and a 66% decrease in the need for hospitalization (P<0.05) compared to no pacing (5). Patients also preferred BiV pacing compared to no pacing (P<0.001). The Multicenter InSync Randomized Clinical Evaluation (MIRACLE) study not only confirmed many of the findings of the MUSTIC trial, but also showed improvement in the left ventricular ejection fraction (LVEF) with BiV pacing (+4.6% vs. -0.2%, P<0.001), compared to non-paced controls (6). Such data has led to the classification of BiV pacing in patients with dilated cardiomyopathy as a class IIa recommendation by ACC/AHA/NASPE guidelines (7).
Coronary artery bypass grafting (CABG) in patients with left ventricular dysfunction carries a high mortality (8). Furthermore, patients with a low LVEF have a greater need for intraaortic balloon pump (P<0.0001) and inotropic support (P<0.001) with a longer length of hospital stay (P<0.002) compared with those with normal LVEF (9, 10).
Conduction system abnormalities following CABG are common (11, 12). The majority of these abnormalities are transient and are often managed using temporary epicardial pacing. Hence, all patients that undergo CABG receive epicardial leads as a precautionary measure. These leads are placed on the right or left ventricle and the right atrium. When patients are felt to no longer require these, they are removed easily. The role of BiV pacing in this setting is unknown. Whether patients that have left ventricular dysfunction would have improved post-operative mortality, less need for intraaortic balloon pump and inotropic support, and shorter length of hospital stay is unknown.
Endpoints:
Primary: -Length of ICU stay
Secondary: -In-hospital mortality
After surgery is completed, the patients will receive either usual care, RV pacing, or BiV pacing depending upon their treatment arms. Intraoperative transesophageal echocardiography (TEE) is routinely performed during cardiac surgery. If TEE is being used in the subject images will be recorded with biventricular pacing, right ventricular pacing and no pacing in the first 30 patients studied to quantify changes in vetricular synchrony with biventricular pacing. Once the patient arrives in the SICU hemodynmic monitoring will be performed as usual. All patients return from the operating room with a pulmonary artery catheter. In the first 50 patients the stroke volume will be obtained by thermodilution method using the pulmonary artery catheter in their assigned treatment arm as well as following 2 minutes of right ventricular pacing and again following 2 minutes of biventricular pacing. Pacing will be continued in the assigned treatment arm until all inotropic and intraortic ballon pump support has been weaned off. Crossover in treatment arms is discouraged, but will be at the discretion of the treating physicians. The epicardial pacing leads will be removed as per routine.
Inclusion criteria
Exclusion criteria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Corewell Health East
Other
Prospective Evaluation Of Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00057057
Cardiomyopathies, Cardiomyopathy
Cleveland, Ohio, United States
View Trial DetailsNCT00559338
Cardiomyopathies, Cardiomyopathy
Dallas, Texas, United States
View Trial DetailsNCT01648634
Cardiomyopathies, Cardiomyopathy
Paris, France
View Trial DetailsNCT01261065
Cardiomyopathies, Cardiomyopathy
Houston, Texas, United States
View Trial Details